TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People
Brief Summary: This study was planned to provide new information regarding the role of aliskiren (with or without additional therapy with a diuretic or a Calcium channel blockers (CCB)) in elderly individuals (≥ 65 years) with systolic blood pressure (SBP) 130 to 159 mmHg, in preventing major cardiovascular (CV) events and on global measures of physical, executive and cognitive function.


Options:
A: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: aliskiren; Assigned to Arm(s): N/A
D: Arm Label: Aliskiren + Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Amlodipine | Arm Label: Aliskiren + Hydrochlorothiazide (HCTZ); Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Hydrochlorothiazide (HCTZ) | Arm Label: Aliskiren + Placebo for Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Placebo for Amlodipine | Arm Label: Aliskiren + Placebo for HCTZ; Type: EXPERIMENTAL; Interventions: Drug: Aliskiren, Drug: Placebo for Hydrochlorothiazide (HCTZ) | Arm Label: Amlodipine + Placebo for Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine, Drug: Placebo for Aliskiren | Arm Label: HCTZ + Placebo for Aliskiren; Type: EXPERIMENTAL; Interventions: Drug: Hydrochlorothiazide (HCTZ), Drug: Placebo for Aliskiren | Arm Label: Placebo for Aliskiren + Placebo for Amlodipine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Aliskiren, Drug: Placebo for Amlodipine | Arm Label: Placebo for Aliskiren + Placebo for HCTZ; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Aliskiren, Drug: Placebo for Hydrochlorothiazide (HCTZ) | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren + Amlodipine, Aliskiren + Hydrochlorothiazide (HCTZ), Aliskiren + Placebo for Amlodipine, Aliskiren + Placebo for HCTZ | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Aliskiren + Amlodipine, Amlodipine + Placebo for Aliskiren | Intervention Type: DRUG; Name: Hydrochlorothiazide (HCTZ); Assigned to Arm(s): Aliskiren + Hydrochlorothiazide (HCTZ), HCTZ + Placebo for Aliskiren | Intervention Type: DRUG; Name: Placebo for Aliskiren; Assigned to Arm(s): Amlodipine + Placebo for Aliskiren, HCTZ + Placebo for Aliskiren, Placebo for Aliskiren + Placebo for Amlodipine, Placebo for Aliskiren + Placebo for HCTZ | Intervention Type: DRUG; Name: Placebo for Amlodipine; Assigned to Arm(s): Aliskiren + Placebo for Amlodipine, Placebo for Aliskiren + Placebo for Amlodipine | Intervention Type: DRUG; Name: Placebo for Hydrochlorothiazide (HCTZ); Assigned to Arm(s): Aliskiren + Placebo for HCTZ, Placebo for Aliskiren + Placebo for HCTZ

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate HCl Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD
Brief Summary: This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).


Options:
A: Intervention Type: DRUG; Name: methylphenidate hydrochloride extended-release tablets; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: Adhansia XR; Type: EXPERIMENTAL; Interventions: Drug: Adhansia XR | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Adhansia XR; Assigned to Arm(s): Adhansia XR | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
D: Arm Label: Ritalin LA 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA 20 mg | Arm Label: Ritalin LA 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA 20 mg, Drug: Ritalin LA 30 mg | Arm Label: Ritalin LA 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Ritalin LA 20 mg, Drug: Ritalin LA 30 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ritalin LA 20 mg; Assigned to Arm(s): Ritalin LA 40 mg, Ritalin LA 60 mg, Ritalin LA 80 mg | Intervention Type: DRUG; Name: Ritalin LA 30 mg; Assigned to Arm(s): Ritalin LA 60 mg, Ritalin LA 80 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Due to the increasing demand for colonoscopy in clinical practice, great interest has recently renewed for unsedated colonoscopy. Both Carbon dioxide Insufflation (CO2) and Warm Water Infusion (WWI) have been advocated to improve patient tolerance for colonoscopy as compared to standard Air Insufflation (AI). This study is aimed at evaluating the performance of the above techniques versus AI in unsedated patients.


Options:
A: Arm Label: CO2; Type: EXPERIMENTAL; Interventions: Procedure: CO2 | Arm Label: Warm Water irrigation; Type: EXPERIMENTAL; Interventions: Procedure: Warm water | Intervention Type: PROCEDURE; Name: CO2; Assigned to Arm(s): CO2 | Intervention Type: PROCEDURE; Name: Warm water; Assigned to Arm(s): Warm Water irrigation
B: Arm Label: Water Immersion Colonoscopy; Type: EXPERIMENTAL; Interventions: Procedure: water immersion colonoscopy | Arm Label: Standard Air Colonoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard air colonoscopy | Intervention Type: PROCEDURE; Name: water immersion colonoscopy; Assigned to Arm(s): Water Immersion Colonoscopy | Intervention Type: PROCEDURE; Name: standard air colonoscopy; Assigned to Arm(s): Standard Air Colonoscopy
C: Arm Label: air insufflation; Type: PLACEBO_COMPARATOR; Interventions: Procedure: air insufflation | Arm Label: water immersion; Type: ACTIVE_COMPARATOR; Interventions: Procedure: water immersion | Arm Label: water exchange; Type: ACTIVE_COMPARATOR; Interventions: Procedure: water exchange | Intervention Type: PROCEDURE; Name: air insufflation; Assigned to Arm(s): air insufflation | Intervention Type: PROCEDURE; Name: water immersion; Assigned to Arm(s): water immersion | Intervention Type: PROCEDURE; Name: water exchange; Assigned to Arm(s): water exchange
D: Intervention Type: PROCEDURE; Name: water infusion colonoscopy; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Dietary Cocoa Flavanols on Cardio-pulmonary Exercise Capacity in Human.
Brief Summary: The purpose of this study is to characterize the potential improvement of cocoa flavanols on exercise capacity in highly trained cyclist. A placebo-controlled double-blinded randomized control study will be performed in 13 highly trained cyclist (crossover design). Participants will perform a baseline exercise testing on an ergometer. They will receive either a flavanol-poor or flavanol rich cocoa drink twice daily for one week before a second and third exercise testing is performed. The order of drinks is randomized and balanced (high-flavanol--\>low-flavanol drink or low-flavanol drink--\>high-flavanol drink)


Options:
A: Arm Label: Flavanol rich cocoa; Type: EXPERIMENTAL; Interventions: Other: Cocoa | Arm Label: flavanol poor cocoa drink; Type: EXPERIMENTAL; Interventions: Other: Cocoa | Intervention Type: OTHER; Name: Cocoa; Assigned to Arm(s): Flavanol rich cocoa, flavanol poor cocoa drink
B: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Ischemic Preconditioning | Arm Label: CONTROL; Type: PLACEBO_COMPARATOR; Interventions: Other: Control | Intervention Type: PROCEDURE; Name: Remote Ischemic Preconditioning; Assigned to Arm(s): RIPC | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): CONTROL
C: Arm Label: Sham RIPC; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Sham | Arm Label: Active RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Ischemic Preconditioning | Intervention Type: PROCEDURE; Name: Remote Ischemic Preconditioning; Assigned to Arm(s): Active RIPC | Intervention Type: PROCEDURE; Name: Sham; Assigned to Arm(s): Sham RIPC
D: Arm Label: ExerciseTr; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: Remote ischemic preconditioning group; Type: EXPERIMENTAL; Interventions: Procedure: remote ischemic preconditioning | Arm Label: Control patient group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): ExerciseTr | Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): Remote ischemic preconditioning group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nordic Randomized Phase III Trial of Two Different Durations of Adjuvant Therapy With Intermediate-dose Interferon Alfa-2b in Patients With High-risk Melanoma
Brief Summary: The aim of this study is to evaluate the effect of giving adjuvant treatment with intermediate doses of interferon-alpha2b to patients operated for high risk melanoma. Patients are randomly assigned to either observation only or interferon treatment for 2 different durations. The outcome with respect to overall survival, relapse-free survival, side effects and quality of life is analysed.


Options:
A: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
B: Arm Label: WEX only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Wide Excision | Arm Label: WEX + SLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sentinel Lymph Node Dissection | Arm Label: WEX+SLND+CLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Complete Lymph Node Dissection | Intervention Type: PROCEDURE; Name: Sentinel Lymph Node Dissection; Assigned to Arm(s): WEX + SLND | Intervention Type: PROCEDURE; Name: Complete Lymph Node Dissection; Assigned to Arm(s): WEX+SLND+CLND | Intervention Type: PROCEDURE; Name: Wide Excision; Assigned to Arm(s): WEX only
C: Arm Label: Arm A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm B Interferon 1 year; Type: EXPERIMENTAL; Interventions: Drug: Interferon-alpha2b - 1 year | Arm Label: Arm C Interferon 2 years; Type: EXPERIMENTAL; Interventions: Drug: Interferon-alpha2b - 2 years | Intervention Type: DRUG; Name: Interferon-alpha2b - 1 year; Assigned to Arm(s): Arm B Interferon 1 year | Intervention Type: DRUG; Name: Interferon-alpha2b - 2 years; Assigned to Arm(s): Arm C Interferon 2 years
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of a Perioperative Smoking Cessation Program on Rates of Smoking Cessation/Reduction and Perioperative Complications: a Randomized Clinical Trial.
Brief Summary: The purpose of this study is to determine whether a perioperative smoking cessation program, implemented at least 3 weeks prior to elective surgery, is effective in increasing rates of smoking cessation or reduction. Intraoperative and immediate postoperative complications will also be compared.


Options:
A: Arm Label: Standard support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support | Arm Label: Proactive telephone support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support | Arm Label: Standard support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive (standard) telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Arm Label: Proactive support & offer NRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Proactive telephone support, Drug: Offer of voucher for cost-free Nicotine Replacement Therapy | Intervention Type: BEHAVIORAL; Name: Proactive telephone support; Assigned to Arm(s): Proactive support & offer NRT, Proactive telephone support | Intervention Type: BEHAVIORAL; Name: Reactive (standard) telephone support; Assigned to Arm(s): Standard support, Standard support & offer NRT | Intervention Type: DRUG; Name: Offer of voucher for cost-free Nicotine Replacement Therapy; Assigned to Arm(s): Proactive support & offer NRT, Standard support & offer NRT
B: Arm Label: PRO+NRT+TC; Type: EXPERIMENTAL; Interventions: Other: proactive outreach (PRO), Other: telephone counseling (TC), Other: Nicotine replacement therapy (NRT) | Arm Label: Usual Care (UC); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care (UC) | Intervention Type: OTHER; Name: proactive outreach (PRO); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: telephone counseling (TC); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: Nicotine replacement therapy (NRT); Assigned to Arm(s): PRO+NRT+TC | Intervention Type: OTHER; Name: Usual care (UC); Assigned to Arm(s): Usual Care (UC)
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Smoking cessation program; Type: EXPERIMENTAL; Interventions: Other: Smoking cessation program | Intervention Type: OTHER; Name: Smoking cessation program; Assigned to Arm(s): Smoking cessation program
D: Arm Label: Smoking-cessation treatment + substance treatment as usual; Type: EXPERIMENTAL; Interventions: Other: Smoking-cessation treatment | Arm Label: Substance-treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Smoking-cessation treatment; Assigned to Arm(s): Smoking-cessation treatment + substance treatment as usual

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Unblinded, Single Research Site, Comparator Study of Raisins Versus Alternative Snacks on Cardiovascular Risk Factors In Generally Healthy Subjects
Brief Summary: This trial compared the effects of raisin intake on cardiovascular risk factors compared to common, commercially available, alternative snacks. These cardiovascular risk factors include glucose, blood pressure, lipid levels, body weight, and waist circumference.


Options:
A: Arm Label: DIPI: Danish national dietary guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: DIPI: Specific IHD dietary guideline; Type: ACTIVE_COMPARATOR; Interventions: Other: DIPI | Arm Label: Normal dietary habits; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: DIPI; Assigned to Arm(s): DIPI: Danish national dietary guidelines, DIPI: Specific IHD dietary guideline
B: Arm Label: Alternative Snack Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Alternative Snack Comparator | Arm Label: Raisin Group; Type: EXPERIMENTAL; Interventions: Other: Raisins | Intervention Type: OTHER; Name: Alternative Snack Comparator; Assigned to Arm(s): Alternative Snack Group | Intervention Type: OTHER; Name: Raisins; Assigned to Arm(s): Raisin Group
C: Intervention Type: OTHER; Name: Dietary fructose; Assigned to Arm(s): N/A
D: Arm Label: Healthy Choices; Type: OTHER; Interventions: Behavioral: Healthy Choices | Arm Label: Diet Substitution A; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary substitution A | Arm Label: Diet Substitution B; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Substitution B | Intervention Type: BEHAVIORAL; Name: Dietary substitution A; Assigned to Arm(s): Diet Substitution A | Intervention Type: BEHAVIORAL; Name: Dietary Substitution B; Assigned to Arm(s): Diet Substitution B | Intervention Type: BEHAVIORAL; Name: Healthy Choices; Assigned to Arm(s): Healthy Choices

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continuum of Care, From the Emergency Ward to Living at Home - Implementation and Evaluation of an Intervention for Frail Elderly People
Brief Summary: The present study "Continuum of care for frail elderly people" form part of the research programme "Support for frail elderly persons - from prevention to palliation" (www.vardalinstitutet.net) which comprises research into three interventions. The program comprises interventions addressing frail elderly people in different phases of the disablement process, from elderly people who are beginning to develop frailty to very frail elderly people receiving palliative care.

The intervention "Continuum of care for frail elderly people" addresses elderly people who are frail and that have a great risk of high health care consumption. The hypothesis is that an intervention program for frail elderly people can reduce the number of visits to the emergency department, increase the life satisfaction and maintain the functional ability. The intervention, including an early geriatric assessment at the emergency department, early family support, a case manager in the community with a multi-professional team and active follow-up by the case manager, contributes to early recognition of the elderly people's need of information, care and rehabilitation and of informal caregivers' need of information. It enhances the transfer of information and integrates the care between different caregivers and different care levels, thereby better recognize frail elderly people's needs. Specifically, this study is expected to show that the intervention has a positive effect on the frail elderly person's functional ability, life satisfaction, satisfaction with health and social care, and health care consumption.


Options:
A: Arm Label: Control arm= usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention arm; Type: OTHER; Interventions: Other: intervention | Intervention Type: OTHER; Name: intervention; Assigned to Arm(s): Intervention arm
B: Intervention Type: BEHAVIORAL; Name: Geriatric Resources for Assessment & Care of Elders (GRACE); Assigned to Arm(s): N/A
C: Arm Label: Conventional care, controlgroup; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: integrated health care chain; Type: EXPERIMENTAL; Interventions: Other: integrated health care chain | Intervention Type: OTHER; Name: integrated health care chain; Assigned to Arm(s): integrated health care chain
D: Intervention Type: BEHAVIORAL; Name: Preventive Primary Care Outreach; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Re-engagement in Evidence-based Quit Line Treatment for Low Income Smokers
Brief Summary: The purpose of this proposed study is to develop, refine and test the use of Interactive Voice Response (IVR) technology as a means of increasing re-engagement of low income smokers in telephone support for tobacco cessation (quit lines). If this strategy proves to be acceptable and feasible, it may offer a technological solution to increase access to and utilization of a widely available evidence-based form of behavioral treatment for low income smokers.

The primary aims of this research are to:

1. Develop an IVR system that delivers tailored audio messages to increase low income smokers' re-engagement in treatment offered by two state quit lines (Washington and Indiana). The investigators will develop: a) a menu of audio messages that can be delivered by an IVR system; b) an IVR algorithm (i.e., a set of decision rules) to make proactive automated calls to deliver brief, tailored messages for re-engaging low income smokers who previously used the quit line.
2. Evaluate the feasibility and efficacy of an IVR system as a tool to re-engage low income smokers into quit line treatment measured by number of IVR calls answered, number of smokers who re-engage in treatment and satisfaction with IVR calls. Hypothesis 2.1 - It is hypothesized that the rates of re-engagement into treatment among those receiving the IVR intervention will be higher than smokers not proactively invited to re-engage in quit line services.


Options:
A: Arm Label: Reminder and Outreach Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Reminder and Outreach Intervention | Arm Label: Usual Care Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reminder and Outreach Intervention; Assigned to Arm(s): Reminder and Outreach Intervention
B: Arm Label: Exercise Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity counseling | Arm Label: Contact Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity counseling; Assigned to Arm(s): Exercise Counseling
C: Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard Care | Arm Label: Extended Care Management; Type: EXPERIMENTAL; Interventions: Other: Extended Care Management | Intervention Type: OTHER; Name: Extended Care Management; Assigned to Arm(s): Extended Care Management | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
D: Arm Label: Life Style Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: IVR intervention | Arm Label: Life Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: IVR control | Intervention Type: BEHAVIORAL; Name: IVR intervention; Assigned to Arm(s): Life Style Counseling | Intervention Type: BEHAVIORAL; Name: IVR control; Assigned to Arm(s): Life Counseling

Answer: D